Anticancer Evaluation of Novel Benzofuran-Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Epidermal growth factor receptor (EGFR) is a key driver in non-small-cell lung cancer (NSCLC).
• Targeting EGFR offers a promising therapeutic strategy for NSCLC treatment.
• Development of novel inhibitors is crucial, especially for resistant mutations.

Purpose of the Study:

• To synthesize and identify novel EGFR inhibitors.
• To evaluate the efficacy of identified compounds against NSCLC cell lines.
• To investigate the inhibitory effects on mutant EGFR forms.

Main Methods:

• Synthesis of a benzofuran-indole hybrid chemical library.
• In vitro screening for EGFR inhibitory activity.
• Assessment of anticancer effects on NSCLC cell lines (PC9, A549).
• Evaluation of inhibitory effects on double mutant L858R/T790M EGFR.

Main Results:

• Compound 8aa identified as a potent and selective EGFR inhibitor.
• 8aa exhibited selective anticancer effects on PC9 and A549 NSCLC cell lines.
• 8aa demonstrated significant inhibition against the L858R/T790M EGFR double mutant.
• 8aa effectively blocked EGFR signaling, cell viability, and migration in NSCLC cells.

Conclusions:

• The benzofuran-indole derivative 8aa is a novel EGFR inhibitor.
• 8aa shows potential as a therapeutic candidate for NSCLC patients with EGFR mutations.
• Further investigation into 8aa's mechanism and efficacy is warranted.